Wells Fargo raised the firm’s price target on Wave Life Sciences (WVE) to $14 from $13 and keeps an Overweight rating on the shares. The firm notes the WVE-007 update included 600mg SAD data, which looked better than low/mid doses on M/Z-AAT and seems protective. However, the efficacy is lower than BEAM-302. Wells is moving probability of success up to 33%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences Signals Momentum in Earnings Call
- Wave Life Sciences price target lowered to $13 from $18 at H.C. Wainwright
- Wave Life Sciences: Buy Rating Reaffirmed as WVE-006 Data Strengthen Case for Accelerated Pathway; $15 Price Target Maintained
- Wave Life Sciences advances WVE-006 RNA editing trial
- Wave Life Sciences announces updated data from RestorAATion-2 trial of WVE-006